Suzuken (9987) Q3 2026 earnings summary

Executive summary

• Revenue/net sales rose 2.6% year-over-year, driven by growth in specialty drug contract distribution and the ethical drug market, despite a decline in COVID-19-related product sales.

• Operating profit decreased 8.6% year-over-year due to higher procurement costs, inflation-driven expenses, and a shift in sales mix toward lower-margin specialty drugs.

• Net income/profit attributable to owners increased 1.1%, supported by a significant gain from the sale of cross-held/investment securities.

• The company advanced its medium-term management plan, focusing on business reform and digital health/logistics infrastructure enhancements.

Financial highlights

• Consolidated net sales: ¥1,885.6B, up ¥46.9B (2.6%) year-over-year.

• Operating profit: ¥27.2B, down ¥2.5B (8.6%) year-over-year.

• Net income attributable to owners: ¥31.0B, up ¥0.3B (1.1%) year-over-year.

• Ordinary profit decreased 5.2% year-over-year to ¥29.3B.

• Extraordinary income included a ¥14.9B gain from the sale of investment securities.

Outlook and guidance

• Full-year net sales forecast: ¥2,468.0B.

• Full-year operating profit forecast: ¥33.6B.

• Full-year net income forecast: ¥32.8B.

• Dividend forecast: ¥100 per share, maintaining a total payout ratio above 100%.

• No changes to previously announced financial forecasts.